The JAK2 pathway is activated in idiopathic pulmonary fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal fibrotic disorder, with no curative therapies. The signal transducer and activator of transcription 3 (STAT3) protein is activated in lung fibroblasts and alveolar type II cells (ATII), thereby contributing to lung fibrosis in IPF. Although activation of Janus kinase 2 (JAK2) has been implicated in proliferative disorders, its role in IPF is unknown. The aim of this study was to analyze JAK2 activation in IPF, and to determine whether JAK2/STAT3 inhibition is a potential therapeutic strategy for this disease. METHODS AND RESULTS: JAK2/p-JAK2 and STAT3/pSTAT3 expression was evaluated using quantitative real time-PCR, western blotting, and immunohistochemistry. Compared to human healthy lung tissue (n = 10) both proteins were upregulated in the lung tissue of IPF patients (n = 12). Stimulating primary ATII and lung fibroblasts with transforming growth factor beta 1 or interleukin (IL)-6/IL-13 activated JAK2 and STAT3, inducing epithelial to mesenchymal and fibroblast to myofibroblast transitions. Dual p-JAK2/p-STAT3 inhibition with JSI-124 or silencing of JAK2 and STAT3 genes suppressed ATII and the fibroblast to myofibroblast transition, with greater effects than the sum of those obtained using JAK2 or STAT3 inhibitors individually. Dual rather than single inhibition was also more effective for inhibiting fibroblast migration, preventing increases in fibroblast senescence and Bcl-2 expression, and ameliorating impaired autophagy. In rats administered JSI-124, a dual inhibitor of p-JAK2/p-STAT3, at a dose of 1 mg/kg/day, bleomycin-induced lung fibrosis was reduced and collagen deposition in the lung was inhibited, as were JAK2 and STAT3 activation and several markers of fibrosis, autophagy, senescence, and anti-apoptosis. CONCLUSIONS: JAK2 and STAT3 are activated in IPF, and their dual inhibition may be an attractive strategy for treating this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, mice that are unable to produce these reactive oxygen species are protected against the fibrosis from bleomycin [182].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [182]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680
Pathogenesis of Idiopathic Pulmonary Fibrosis
Wolters, P. J., Collard, H. R., & Jones, K. D. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104706 · Cited by 862
Blaskovich, M. A., Sun, J., Cantor, A. B., Turkson, J., Jove, R., & Sebti, S. M. (2003) · PubMed · Cited by 643
Janus kinases: components of multiple signaling pathways
Rane, S. G., & Reddy, E. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203925 · Cited by 466
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
Chaudhary, N. I., Roth, G. J., Hilberg, F., Müller-Quernheim, J., Prasse, A., Zissel, G., Schnapp, A., & Park, J. E. (2007) · European Respiratory Journal · doi:10.1183/09031936.00152106 · Cited by 386
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 373
Milara, J., Peiró, T., Serrano, A., & Cortijo, J. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-201761 · Cited by 324
Self-citationNefedova, Y., Nagaraj, S., Rosenbauer, A., Muro-Cacho, C., Sebti, S. M., & Gabrilovich, D. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0529 · Cited by 318
Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203947 · Cited by 290
Cited by
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“, 2017), and promoting apoptosis resistance of fibroblasts (Moodley et al., 2003; Habiel and Hogaboam, 2014; Xu et al., 2014a; Milara et al., 2018), aberrant EMT (Kasembeli et al.”
BackgroundRole of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
Montero, P., Milara, J., Roger, I., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126211 · Cited by 254
Self-citationSingh, S. J., Baldwin, M. M., Daynes, E., Evans, R. A., Greening, N. J., Jenkins, R. G., Lone, N. I., McAuley, H., Mehta, P., Newman, J., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00159-5 · Cited by 187
Zhang, J., Wang, D., Wang, L., Wang, S., Roden, A. C., Zhao, H., Li, X., Prakash, Y. S., Matteson, E. L., Tschumperlin, D. J., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00301.2018 · Cited by 194
Kasembeli, M. M., Bharadwaj, U., Robinson, P., & Tweardy, D. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082299 · Cited by 199
“These observations are supported by numerous other studies that clearly establish the anti-apoptotic role of STAT3 in fibrosis [52,187,188].”
BackgroundResultInfluential
Metadata
- Authors
- Milara, J., Hernandez, G., Ballester, B., Morell, A., Roger, I., Montero, P., Escrivá, J., Lloris, J. M., Molina-Molina, M., Morcillo, E., & Cortijo, J.
- Affiliations
- Universitat Jaume I (ES)
- Universitat Politècnica de València (ES)
- Universitat de València (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Corresponding author
- Milara, Javier
- ORCID
- Venue
- Respiratory Research
- Published
- 2018-02-06
- Volume
- 19
- Issue
- 1
- Pages
- 24-24
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- PMC
- PMC5801676
- OpenAlex
- W2799581227
- Cited by
- 188
- References
- 36
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 26 · 2023: 40 · 2022: 32 · 2021: 24 · 2020: 15 · 2019: 12 · 2018: 3
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Respiratory Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (publishedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by)
- Repositori UJI (Universitat Jaume I) (submittedVersion, cc-by-sa)
- Funders
- Ministerio de Educación, Cultura y Deporte (SAF2014-55322-P, SAF2015-65368-R)
- Instituto de Salud Carlos III (PI14/01733; PI17/02158)
- CIBERES (CB06/06/0027)
- Ministerio de Economía y Competitividad (TRA2009-0311)
- Generalitat Valenciana (Prometeo II/2013/014, 2017/023, ACIF/2016/341)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, JAK2, STAT3, JSI-124, alveolar type II cells, lung fibroblasts, epithelial-mesenchymal transition, myofibroblast differentiation, fibroblast senescence, autophagy, bleomycin-induced lung fibrosis, TGF-β1, Bcl-2, collagen deposition
- MeSH terms
- A549 Cells, Adult, Aged, Animals, Enzyme Activation, Female, Fibroblasts, Humans, Male, Middle Aged, Triterpenes, Signal Transduction, STAT3 Transcription Factor, Rats, Janus Kinase 2, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The JAK2 pathway is activated in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-018-0728-9
- The paper
- Milara, J., Hernandez, G., Ballester, B., Morell, A., Roger, I., Montero, P., Escrivá, J., Lloris, J. M., Molina-Molina, M., Morcillo, E., & Cortijo, J. (2018). The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-018-0728-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.